David Nutt
Edmond J. Safra Professor of Neuropsychopharmacology
Data updated
Research Footprint
David Nutt appears in 129 tracked papers (2010–2026), most studied alongside Psilocybin, LSD and MDMA, across Depressive Disorders, Neuroimaging & Brain Measures and Anxiety Disorders.
Most-cited paper: Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (1520 citations).
Frequent co-authors: Robin Carhart-Harris, David Erritzoe and Leor Roseman.
Background & Research
David Nutt is an English neuropsychopharmacologist and a leading authority on the effects of drugs on the brain and society. He holds the Edmond J. Safra Chair in Neuropsychopharmacology at Imperial College London and is the founder of Drug Science, an independent body providing evidence-based drug information. His career has focused on addiction, anxiety, and sleep, and he has been a vocal advocate for the therapeutic use of psychedelics and scientific drug policy.
Key Impact
Leading figure in neuropsychopharmacology and drug policy reform; founder of Drug Science.
Collaboration Network
111 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations David Nutt is associated with.
Imperial College London
academicEdmond J. Safra Professor of Neuropsychopharmacology
The Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →Drug Science
Founder & Chair
Drug Science is a UK-based independent, science-led drugs charity founded in 2010 and headquartered in London, with work aimed at the UK public and international audiences. It focuses on building an evidence base for drug harms and benefits, and on equipping the public, media, and policymakers with scientific information to support sensible drug laws and evidence-based debate. In psychedelics, Drug Science is an explicit field actor rather than a peripheral observer. Its Medical Psychedelics Working Group promotes evidence-based psychedelic research and access, including support for removing psychedelic drugs from Schedule 1 restrictions, improving regulatory pathways for medical use, and producing educational resources for healthcare professionals and the public. The organization also publishes commentary and research-led content on psychedelic policy, clinical development, and public attitudes, and has recent documented activity around psilocybin regulation, psychedelic terminology, and UK research ecosystem updates.
View stakeholder →COMPASS Pathways
Public BiotechCOMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
View stakeholder →